What Is Genuinely Working
Organic revenue growth accelerated to 3.5%, with positive organic performance across all regions; Q2 organic growth reached 4.7%. Interim Report pp. 7-9, 12, 35-36, 69
Adjusted EBITDA increased 3.6% to €298.0 million and the adjusted margin rose 70 basis points to 25.1%. Interim Report pp. 7-9, 12, 35-36, 69
Free cash flow rose to €56.6 million from €37.5 million as net operating capex fell to €45.9 million from €64.4 million. Interim Report pp. 7-9, 12, 35-36, 69
Track Record And Consistency
Medium: the H1 rebound addresses the 2025 guidance cuts and weak Q1 reported earnings, but the improvement is clearest in adjusted measures while Fit4Growth removed revenue, reported EBITDA and net profit declined, and the next operating baseline depends on the GN Hearing transaction. Interim Report pp. 7-9, 12, 35-36, 69
What The Headline Obscures
Reported revenue grew only 0.4% because Fit4Growth streamlining and reorganization removed 3.0 percentage points of revenue and FX removed another 0.9 points; Americas reported revenue fell 5.9%. Interim Report pp. 7-9, 12, 35-36, 69
Reported EBITDA fell 3.5% and reported group profit fell 28.0%, while adjusted EBITDA excluded €21.0 million of items versus €0.7 million a year earlier, including €11.8 million of GN Hearing transaction and integration costs. Interim Report pp. 7-9, 12, 35-36, 69
The headline debt reduction is largely the €449.0 million equity raise earmarked for GN Hearing; on a pro-forma basis excluding it, net financial debt excluding leases was €1.05 billion, essentially unchanged from December 2025. Interim Report pp. 7-9, 12, 35-36, 69
Amplifon has signed a €1.35 billion 24-month senior loan for the remaining GN Hearing cash consideration, so leverage and integration risk will change materially if the transaction closes. Interim Report pp. 7-9, 12, 35-36, 69
Corporate Language, Decoded
What To Watch Next
Bull case: Organic growth stays above 3%, Fit4Growth converts into the guided roughly 100-basis-point adjusted-margin increase, and GN Hearing closes without disrupting cash generation or financing access.
Bear case: The reported revenue base remains constrained by disposals and the US contract exit, adjusted gains fail to reach statutory earnings and cash, or the GN Hearing deal increases leverage and integration costs before synergies materialize.
Measurable watchlist: Organic growth excluding the terminated US managed-care agreement; reported versus adjusted EBITDA and profit; free cash flow after deal costs; pro-forma leverage; GN Hearing approvals, funding, and integration milestones.